{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:10:15Z","timestamp":1782310215312,"version":"3.54.5"},"reference-count":55,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016097","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:23:53Z","timestamp":1755861833000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["FcRn inhibitors for myasthenia gravis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Laura M","family":"White","sequence":"additional","affiliation":[{"name":"Lancaster Medical School; Lancaster University; Lancaster UK"},{"name":"Department of Neurology; Lancashire Teaching Hospitals NHS Foundation Trust; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona J","family":"Clay","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine; Monash University; Southbank Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Forbes","sequence":"additional","affiliation":[{"name":"University of Tasmania; Hobart Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Yann Shern","family":"Keh","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Lilleker","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"},{"name":"The University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; University College London Hospitals NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Storms","sequence":"additional","affiliation":[{"name":"Library & Knowledge Service; Northern Care Alliance NHS Foundation Trust; Oldham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-7030","authenticated-orcid":false,"given":"Katherine C","family":"Dodd","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"},{"name":"The University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Sussman","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"},{"name":"The University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD016097-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"10","key":"10.1002\/14651858.CD016097-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nature Reviews Immunology"},{"issue":"4","key":"10.1002\/14651858.CD016097-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016097-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic, and clinical classification of autoimmune myasthenia gravis","volume":"48-49","author":"Berrih-Aknin","year":"2014","journal-title":"Journal of Autoimmunity"},{"issue":"10","key":"10.1002\/14651858.CD016097-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"Scorsetti","year":"2016","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1002\/14651858.CD016097-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"527\u201331","DOI":"10.1001\/archneur.57.4.527","article-title":"Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia","volume":"57","author":"Mygland","year":"2000","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD016097-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11748-007-0185-8","article-title":"Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis","volume":"56","author":"Okumura","year":"2008","journal-title":"General Thoracic and Cardiovascular Surgery"},{"key":"10.1002\/14651858.CD016097-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Practical Neurology"},{"issue":"3","key":"10.1002\/14651858.CD016097-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD016097-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016097-BIB0014|cit14","first-page":"e16180","article-title":"Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy","volume":"Dec 20","author":"Sacc\u00e0","year":"2023","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016097-BIB0015|cit15","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale Journal of Biology and Medicine"},{"key":"10.1002\/14651858.CD016097-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRn receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Frontiers in Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair","year":"2023","journal-title":"ImmunoTargets and Therapy"},{"key":"10.1002\/14651858.CD016097-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Bril","year":"2021","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0019|cit19","unstructured":"European Medicines Agency Vyvgart (efgartigimod alfa) Summary of Product Characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf"},{"key":"10.1002\/14651858.CD016097-BIB0020|cit20","unstructured":"VYVGART \u2122 (efgartigimod alfa-fcab) injection, for intravenous use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761195s000lbl.pdf"},{"key":"10.1002\/14651858.CD016097-BIB0021|cit21","unstructured":"Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis (ADAPT Jr) https:\/\/clinicaltrials.gov\/study\/NCT04833894"},{"key":"10.1002\/14651858.CD016097-BIB0022|cit22","unstructured":"Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children with Generalized Myasthenia Gravis (ADAPT Jr +) https:\/\/clinicaltrials.gov\/study\/NCT05374590"},{"key":"10.1002\/14651858.CD016097-BIB0023|cit23","unstructured":"A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age with Generalized Myasthenia Gravis (ADAPT Jr SC) https:\/\/clinicaltrials.gov\/study\/NCT06392386"},{"key":"10.1002\/14651858.CD016097-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016097-BIB0025|cit25","unstructured":"RYSTIGGO\u00ae (rozanolixizumab-noli) injection, for subcutaneous use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf"},{"key":"10.1002\/14651858.CD016097-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/1744666X.2022.2136167","article-title":"Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective","volume":"18","author":"Suzuki","year":"2022","journal-title":"Expert Reviews in Clinical Immunology"},{"key":"10.1002\/14651858.CD016097-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0028|cit28","unstructured":"A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis https:\/\/clinicaltrials.gov\/study\/NCT04951622"},{"key":"10.1002\/14651858.CD016097-BIB0029|cit29","unstructured":"A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis https:\/\/clinicaltrials.gov\/study\/NCT05265273"},{"key":"10.1002\/14651858.CD016097-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/acn3.51946","article-title":"Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension","volume":"11","author":"Nowak","year":"2024","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0031|cit31","unstructured":"Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis https:\/\/clinicaltrials.gov\/study\/NCT05403541"},{"key":"10.1002\/14651858.CD016097-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12883-024-03804-y","article-title":"Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report","volume":"24","author":"Ohara","year":"2024","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"9455237","DOI":"10.1155\/2024\/9455237","article-title":"Efgartigimod as rescue medication in a patient with therapy-refractory myasthenic crisis","volume":"2024","author":"Alhaj Omar","year":"2024","journal-title":"Case Reports in Neurological Medicine"},{"key":"10.1002\/14651858.CD016097-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/mus.28178","article-title":"Efgartigimod infusion in the treatment regimen for myasthenic crisis: a case report","volume":"70","author":"Sun","year":"2024","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD016097-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1321058","DOI":"10.3389\/fneur.2024.1321058","article-title":"Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod","volume":"15","author":"Watanabe","year":"2024","journal-title":"Frontiers in Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"175628642412548","DOI":"10.1177\/17562864241254895","article-title":"Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report","volume":"17","author":"Zhang","year":"2024","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD016097-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD016097-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1418503","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD016097-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":". Annals of Clinical and Translational Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Science Reports"},{"key":"10.1002\/14651858.CD016097-BIB0041|cit41","first-page":"e2661","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Bril","year":"2019","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":".Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"10.1002\/14651858.CD016097-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"5","key":"10.1002\/14651858.CD016097-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD016097-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable tool for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016097-BIB0046|cit46","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD016097-BIB0047|cit47","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD016097-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016097-BIB0049|cit49","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD016097-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016097-BIB0051|cit51","unstructured":"Outcome Reporting Bias in Trials (ORBIT) https:\/\/outcome-reporting-bias.org\/"},{"issue":"7109","key":"10.1002\/14651858.CD016097-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016097-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016097-BIB0054|cit54","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD016097-BIB0055|cit55","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:24:01Z","timestamp":1755861841000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016097"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016097","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}